INDIANAPOLIS (AP) — Eli Lilly continues to again a possible COVID-19 therapy regardless of analysis exhibiting that it might not work on hospitalized sufferers.

The drugmaker mentioned Tuesday it stays assured that its drug might cease COVID from creating in different sufferers. Researchers are nonetheless learning the drug in gentle to reasonably in poor health sufferers, to attempt to forestall hospitalization and extreme sickness.

U.S. authorities officers mentioned Monday that they put an early finish to a examine testing the antibody drug in hospitalized sufferers as a result of it doesn’t appear to be serving to them.

Antibodies are proteins the physique makes when an an infection happens; they connect to a virus and assist it’s eradicated.

Lilly shares tumbled in early-morning buying and selling Tuesday after the corporate additionally laid out disappointing third-quarter outcomes.

The drugmaker mentioned its web revenue fell 4% to $1.21 billion, partly as a consequence of $125 in analysis and improvement prices for creating potential COVID-19 therapies.

International income climbed 5% to $5.74 billion, and adjusted earnings totaled $1.54 per share.

Analysts anticipated, on common, earnings of $1.71 per share on $5.87 billion in income, based on FactSet.

Shares of Indianapolis-based Eli Lilly and Co. fell 4% to $136.01 earlier than markets opened.